PDF(Pubmed)
Abstract：
UNASSIGNED: The impact of previous SARS-CoV-2 infection on the systemic immune response during tuberculosis (TB) disease has not been explored.
UNASSIGNED: An observational, cross-sectional cohort was established to evaluate the systemic immune response in persons with pulmonary tuberculosis with or without previous SARS-CoV-2 infection. Those participants were recruited in an outpatient referral clinic in Rio de Janeiro, Brazil. TB was defined as a positive Xpert-MTB/RIF Ultra and/or a positive culture of Mycobacterium tuberculosis from sputum. Stored plasma was used to perform specific serology to identify previous SARS-CoV-2 infection (TB/Prex-SCoV-2 group) and confirm the non- infection of the tuberculosis group (TB group). Plasmatic cytokine/chemokine/growth factor profiling was performed using Luminex technology. Tuberculosis severity was assessed by clinical and laboratory parameters. Participants from TB group (4.55%) and TB/Prex-SCoV-2 (0.00%) received the complete COVID-19 vaccination.
UNASSIGNED: Among 35 participants with pulmonary TB, 22 were classified as TB/Prex-SCoV-2. The parameters associated with TB severity, together with hematologic and biochemical data were similar between the TB and TB/Prex-SCoV-2 groups. Among the signs and symptoms, fever and dyspnea were significantly more frequent in the TB group than the TB/Prex-SCoV-2 group (p < 0,05). A signature based on lower amount of plasma EGF, G-CSF, GM-CSF, IFN-α2, IL-12(p70), IL-13, IL-15, IL-17, IL-1β, IL-5, IL-7, and TNF-β was observed in the TB/Prex-SCoV-2 group. In contrast, MIP-1β was significantly higher in the TB/Prex-SCoV-2 group than the TB group.
UNASSIGNED: TB patients previously infected with SARS-CoV-2 had an immunomodulation that was associated with lower plasma concentrations of soluble factors associated with systemic inflammation. This signature was associated with a lower frequency of symptoms such as fever and dyspnea but did not reflect significant differences in TB severity parameters observed at baseline.
UNASSIGNED: An observational, cross-sectional cohort was established to evaluate the systemic immune response in persons with pulmonary tuberculosis with or without previous SARS-CoV-2 infection. Those participants were recruited in an outpatient referral clinic in Rio de Janeiro, Brazil. TB was defined as a positive Xpert-MTB/RIF Ultra and/or a positive culture of Mycobacterium tuberculosis from sputum. Stored plasma was used to perform specific serology to identify previous SARS-CoV-2 infection (TB/Prex-SCoV-2 group) and confirm the non- infection of the tuberculosis group (TB group). Plasmatic cytokine/chemokine/growth factor profiling was performed using Luminex technology. Tuberculosis severity was assessed by clinical and laboratory parameters. Participants from TB group (4.55%) and TB/Prex-SCoV-2 (0.00%) received the complete COVID-19 vaccination.
UNASSIGNED: Among 35 participants with pulmonary TB, 22 were classified as TB/Prex-SCoV-2. The parameters associated with TB severity, together with hematologic and biochemical data were similar between the TB and TB/Prex-SCoV-2 groups. Among the signs and symptoms, fever and dyspnea were significantly more frequent in the TB group than the TB/Prex-SCoV-2 group (p < 0,05). A signature based on lower amount of plasma EGF, G-CSF, GM-CSF, IFN-α2, IL-12(p70), IL-13, IL-15, IL-17, IL-1β, IL-5, IL-7, and TNF-β was observed in the TB/Prex-SCoV-2 group. In contrast, MIP-1β was significantly higher in the TB/Prex-SCoV-2 group than the TB group.
UNASSIGNED: TB patients previously infected with SARS-CoV-2 had an immunomodulation that was associated with lower plasma concentrations of soluble factors associated with systemic inflammation. This signature was associated with a lower frequency of symptoms such as fever and dyspnea but did not reflect significant differences in TB severity parameters observed at baseline.
摘要：
■尚未探索先前的SARS-CoV-2感染对结核病（TB）疾病期间的全身免疫反应的影响。
■观测，我们建立了横断面队列,以评估既往有或没有SARS-CoV-2感染的肺结核患者的全身免疫反应.这些参与者是在里约热内卢的门诊转诊诊所招募的，巴西。TB被定义为来自痰的结核分枝杆菌的阳性Xpert-MTB/RIFUltra和/或阳性培养物。使用储存的血浆进行特异性血清学以鉴定先前的SARS-CoV-2感染(TB/Prex-SCoV-2组)并确认结核组(TB组)的非感染。使用Luminex技术进行血浆细胞因子/趋化因子/生长因子分析。通过临床和实验室参数评估结核病的严重程度。来自TB组（4.55％）和TB/Prex-SCoV-2（0.00％）的参与者接受了完整的COVID-19疫苗接种。
■在35名肺结核患者中，22个被分类为TB/Prex-SCoV-2。与TB严重性关联的参数，TB组和TB/Prex-SCoV-2组之间的血液学和生化数据相似.在体征和症状中，与TB/Prex-SCoV-2组相比，TB组的发热和呼吸困难发生率明显更高（p<0.05）。基于较低量的血浆EGF的签名，G-CSF,GM-CSF,IFN-α2，IL-12（p70），IL-13、IL-15、IL-17、IL-1β、在TB/Prex-SCoV-2组中观察到IL-5、IL-7和TNF-β。相比之下,TB/Prex-SCoV-2组的MIP-1β明显高于TB组。
■先前感染SARS-CoV-2的结核病患者具有免疫调节作用，这与与全身性炎症相关的可溶性因子的血浆浓度降低有关。该特征与较低频率的症状(例如发热和呼吸困难)相关,但不反映基线时观察到的TB严重度参数的显著差异。
■观测，我们建立了横断面队列,以评估既往有或没有SARS-CoV-2感染的肺结核患者的全身免疫反应.这些参与者是在里约热内卢的门诊转诊诊所招募的，巴西。TB被定义为来自痰的结核分枝杆菌的阳性Xpert-MTB/RIFUltra和/或阳性培养物。使用储存的血浆进行特异性血清学以鉴定先前的SARS-CoV-2感染(TB/Prex-SCoV-2组)并确认结核组(TB组)的非感染。使用Luminex技术进行血浆细胞因子/趋化因子/生长因子分析。通过临床和实验室参数评估结核病的严重程度。来自TB组（4.55％）和TB/Prex-SCoV-2（0.00％）的参与者接受了完整的COVID-19疫苗接种。
■在35名肺结核患者中，22个被分类为TB/Prex-SCoV-2。与TB严重性关联的参数，TB组和TB/Prex-SCoV-2组之间的血液学和生化数据相似.在体征和症状中，与TB/Prex-SCoV-2组相比，TB组的发热和呼吸困难发生率明显更高（p<0.05）。基于较低量的血浆EGF的签名，G-CSF,GM-CSF,IFN-α2，IL-12（p70），IL-13、IL-15、IL-17、IL-1β、在TB/Prex-SCoV-2组中观察到IL-5、IL-7和TNF-β。相比之下,TB/Prex-SCoV-2组的MIP-1β明显高于TB组。
■先前感染SARS-CoV-2的结核病患者具有免疫调节作用，这与与全身性炎症相关的可溶性因子的血浆浓度降低有关。该特征与较低频率的症状(例如发热和呼吸困难)相关,但不反映基线时观察到的TB严重度参数的显著差异。
